About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Drug Has Potential to Treat Neonatal Seizures

by Ramya Rachamanti on May 16, 2019 at 5:15 PM
Font : A-A+

New Drug Has Potential to Treat Neonatal Seizures

Gluconate present in fruit and honey found to act like an anticonvulsant controlling seizures by targeting chloride channel activity in neonatal neurons of rodent models. This could open up new avenue for treating epilepsy in human newborns. This study led by Penn State researchers was published in the journal Molecular Brain.

"Neonates are the most vulnerable population to seizures but there is still no effective medication for the treatment of neonatal epilepsy," said Gong Chen, professor of biology and the Verne M. Willaman Chair in Life Sciences at Penn State and the leader of the research team. "The incidence of epilepsy is highest in the first year of life, with two to four infant babies suffering from neonatal epilepsy for every 1,000 live births in the United States. Unfortunately, so far there is no effective drug available that is specifically developed for neonatal epilepsy patients."

Advertisement


Over the past decades, many drugs have been developed to treat epilepsy in adults. However, neonatal epilepsy patients are often resistant to or do not respond to current anti-epilepsy drugs, and long-term use of some of these treatments may have side effects on brain development. In the current study, Chen and his colleagues demonstrated that gluconate can inhibit seizure activity in neonatal neurons. More importantly, gluconate suppresses seizure activity in neonatal animals more effectively than in adults.

"This is truly exciting because we have finally identified a potential anticonvulsant drug that shows preference to inhibit neonatal seizure activity," said Chen.
Advertisement

Gluconate is already widely used in the food and pharmaceutical industries as an inactive food or drug additive. For example, it can bind with metal ions to form stable gluconate salts, such as calcium-gluconate, potassium-gluconate, and zinc-gluconate, that are used for the uptake of metal-ion supplements.

"Gluconate is a small organic compound that is produced through the oxidization of glucose in many plants, fruits, and honey," said Zheng Wu, an assistant research professor at Penn State and the first author of the paper. "It has minimal side effects when compared to other organic ions. Because of this, our discovery of its anti-seizure function in neonates could have an accelerated path toward therapeutic development for use in the treatment of neonatal epilepsy."

The research team found that gluconate inhibits neonatal seizures by targeting what are known as CLC-3 chloride channels. These channels mediate a large ion current in neonatal brains but are less active in adult brains. Gluconate appears to be too large to pass through the small openings of the CLC-3 channels and therefore acts as a channel blocker.

"We were surprised that gluconate targeted CLC-3 chloride channels because they have been associated with regulating neuronal transmission, glioma proliferation, and neuron cell death, but until now, there was no mention of neonatal seizure at all," said Wu. "Here we found not only that CLC-3 chloride channels are highly expressed in the neonatal brain but also that they are closely related to neonatal seizures. Importantly, gluconate not only blocks the CLC-3 chloride channels but it also significantly inhibits neonatal seizure activity. Its neonatal activity makes it a great specific target for neonatal anti-epilepsy drugs."

In addition to gluconate, the research team also showed that a ketone body called £]-HB, which is generated in the liver under a ketogenic (low-carb, high-fat) diet, can also act as an inhibitor of CLC-3 chloride channels and suppress neonatal seizure activity. In fact, ketogenic diets have been used to control some childhood epilepsies, but often with unwanted side effects in a small number of children.

"The similar effects of gluconate and a ketone body in inhibiting both CLC-3 chloride channels and neonatal seizures may suggest a better treatment than a ketogenic diet in suppressing neonatal seizures," said Chen. "Our studies not only identify a new drug target, the CLC-3 chloride channels, for neonatal epilepsy but also discovered two potential anticonvulsant drugs, gluconate and the ketone body £]-HB, that can suppress neonatal seizures. Our work also opens a new avenue for other scientists to design even more specific and potent blockers for CLC-3 chloride channels to treat neonatal epilepsy."



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Child Health News

Elevated Hair Cortisol Levels in Newborns Cause Sleep Difficulties
Sleep patterns of infants can be anticipated based on cortisol levels during the later stages of pregnancy, says a new study to be presented at the annual meeting of SLEEP 2023.
 Baby Talk: How Boy and Girl Babies' Speech Differ During Infancy
Analyzing the earliest sex differences in language-related activities, recent research showed boys produced significantly more speech-like vocalizations (protophones) than girls.
Children Don't Always Outgrow Stuttering, but Speech Therapy can be Beneficial
A mother found a team at Saint Louis University's Speech-Language and Hearing Clinic that empowered her daughter to communicate with increased confidence in different settings.
Stunted Growth in North Korean Kids: What You Need to Know
In 2022, the number of North Korean kids falling under the obese category stood at 47,500 compared with 25,100 in 2012.
Fatty Acid in Breast Milk Linked to Improved Heart Function
In mice the maternal milk provides a key signal that instructs cardiomyocytes to activate lipid metabolism.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Drug Has Potential to Treat Neonatal Seizures Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests